Novartis’ Reclast Gains Paget’s Approval, But Still Waiting On Osteoporosis
Executive Summary
Novartis' Paget's disease treatment Reclast (zoledronic acid) will launch with an apparent pricing advantage over the current standard of care, Proctor & Gamble's Actonel (risedronate)